Pfizer Inc. (NYSE:PFE) Stake Boosted by Onyx Bridge Wealth Group LLC

Onyx Bridge Wealth Group LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 10.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 19,042 shares of the biopharmaceutical company’s stock after purchasing an additional 1,841 shares during the period. Onyx Bridge Wealth Group LLC’s holdings in Pfizer were worth $548,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in PFE. Adage Capital Partners GP L.L.C. lifted its stake in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC bought a new stake in Pfizer in the fourth quarter valued at $255,000. Brookstone Capital Management lifted its stake in Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after buying an additional 212,369 shares during the last quarter. ETF Store Inc. lifted its stake in Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 727 shares during the last quarter. Finally, KLCM Advisors Inc. lifted its stake in Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE:PFE traded up $0.61 during mid-day trading on Friday, reaching $26.00. 38,372,801 shares of the stock were exchanged, compared to its average volume of 34,236,664. The business has a fifty day moving average price of $27.11 and a 200 day moving average price of $28.68. The firm has a market capitalization of $147.23 billion, a PE ratio of 72.19, a PEG ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.14 EPS. Research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.